This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2018-03-28PC DrugAllergySubstance Call Minutes"
Jump to navigation
Jump to search
(Created page with " Back to Allergy_&_Intolerance_Drug_Sub-project ===Meeting Information=== {|border="1" cellpadding="2" cellspacing="0" <!---============================================...") |
|||
| Line 105: | Line 105: | ||
### We can build (have built) an RxNorm-UNII map from NLM RxMix, but since G-SRS is using IDMP we don't know if vanilla UNII is correct. | ### We can build (have built) an RxNorm-UNII map from NLM RxMix, but since G-SRS is using IDMP we don't know if vanilla UNII is correct. | ||
## We'll need some explanatory text either way. | ## We'll need some explanatory text either way. | ||
| − | # | + | # Comment 50 suggests adding a type field to the medication table, and it was voted persuasive. On further consideration, the participants agree this is more redundant information than is necessary. |
| + | # Comment 52 suggests adjusting the percentages to represent the fraction of the total rather than of the mapped subset. I.e., the percentages should sum to the 97.7% of total instances, not 100% of instances mapped. On further consideration, participants agreed this would introduce methodological questions that would require a great deal of effort to resolve, with limited benefit. We have added a key to the document defining the data in the columns. | ||
| + | # Review of vaccine/egg guidance | ||
| + | ## Two sources. Citation/link for first source not found. Open issue. | ||
| + | # VSAC roles | ||
| + | ## Need an author credential and a steward credential in VSAC; whether to use existing (e.g., HL7 Terminology) or new (e.g., HL7 PC), or something else. | ||
| + | ## We presume steward will be PC; don't really care who author is as long as we have one. | ||
| + | ## HTA responds it's not them; talk to Vocabulary. | ||
| + | ## In process. | ||
| + | # VSAC metadata | ||
| + | ## drafts complete; in current document | ||
| + | |||
| Line 111: | Line 122: | ||
## CCDA: Emma, Lisa | ## CCDA: Emma, Lisa | ||
## FHIR: Michelle | ## FHIR: Michelle | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
===Meeting Outcomes=== | ===Meeting Outcomes=== | ||
Revision as of 12:21, 29 March 2018
Back to Allergy_&_Intolerance_Drug_Sub-project
Meeting Information
| HL7 Negation Requirements Meeting Minutes Location: Phone |
Date: 2018-03-28 Time: 5:00-6:00 ET | ||
| Facilitator | Jay Lyle | Note taker(s) | Jay Lyle |
| Attendee | Name | Affiliation
| |
| y | Jay Lyle | JP Systems / VA | |
| y | Russ Leftwich | ||
| y | Elaine Ayres | ||
| y | Stephen Chu | ||
| y | George Dixon | ||
| y | Sue Kent | ||
| y | Nancy Orvis | ||
| y | Yanyan Hu | ||
Agenda
Agenda Topics
- Review changes applied to document
Minutes
Minutes/Conclusions Reached:
- Shellfish
- Added 'shellfish-mollusk' to support guidance.
- Corrected 'shellfish' count, 'shellfish - crustacean' count
- Note: SCT concepts are for terrestrial mollusks; request parent concept for terrestrial and marine mollusks.
- Question: do we need a similar approach for marine crustaceans? No identified consumption of terrestrial crustaceans.
- G-SRS
- No response from FDA. We will adopt G-SRS values if and when guidance if provided; if it's not available before we are ready to publish, we will publish without it.
- The only identified source for G-SRS data is clearly labeled 'demo,' and the first sample we tried identified an issue.
- We can build (have built) an RxNorm-UNII map from NLM RxMix, but since G-SRS is using IDMP we don't know if vanilla UNII is correct.
- We'll need some explanatory text either way.
- No response from FDA. We will adopt G-SRS values if and when guidance if provided; if it's not available before we are ready to publish, we will publish without it.
- Comment 50 suggests adding a type field to the medication table, and it was voted persuasive. On further consideration, the participants agree this is more redundant information than is necessary.
- Comment 52 suggests adjusting the percentages to represent the fraction of the total rather than of the mapped subset. I.e., the percentages should sum to the 97.7% of total instances, not 100% of instances mapped. On further consideration, participants agreed this would introduce methodological questions that would require a great deal of effort to resolve, with limited benefit. We have added a key to the document defining the data in the columns.
- Review of vaccine/egg guidance
- Two sources. Citation/link for first source not found. Open issue.
- VSAC roles
- Need an author credential and a steward credential in VSAC; whether to use existing (e.g., HL7 Terminology) or new (e.g., HL7 PC), or something else.
- We presume steward will be PC; don't really care who author is as long as we have one.
- HTA responds it's not them; talk to Vocabulary.
- In process.
- VSAC metadata
- drafts complete; in current document
- FHIR & CCDA adoption
- CCDA: Emma, Lisa
- FHIR: Michelle
Meeting Outcomes
Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2012 Health Level Seven® International. All rights reserved.
